Keros Therapeutics (KROS) EBITDA Margin (2019 - 2025)
Keros Therapeutics' EBITDA Margin was -7498.70% in Q4 2025, down 5758.99 percentage points from -1739.71% a year earlier and down 7393.60 percentage points from the prior quarter.
Powered by 
Analysis
Keros Therapeutics (KROS) EBITDA Margin (2019 - 2025) Analysis & Trends
For FY2025, EBITDA Margin at Keros Therapeutics came in at 28.30%, up 5932.64 percentage points from FY2024.
- EBITDA Margin shows a four-year change of +306.89 percentage points (FY2021 to FY2025).
- In earlier years, EBITDA Margin was -5904.34% in FY2024 (+106099.64 pp), -112003.97% in FY2023 and -278.58% in FY2021.
- The Q4 2025 figure marks the lowest quarterly EBITDA Margin since Q3 2024.
- Compared with a year earlier, EBITDA Margin was higher in five of the last six quarters, with an average year-over-year change of +126085.60 percentage points.
- Per Business Quant data, KROS's EBITDA Margin in the three quarters before Q4 2025 was -105.10% (Q3 2025), -217.12% (Q2 2025) and 72.14% (Q1 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,165.22 Bn | 1,133.81 Bn | 19.71 Bn | 53.49% |
| 2 | Johnson & Johnson | 646.28 Bn | 566.14 Bn | 17.30 Bn | 32.68% |
| 3 | AbbVie | 503.17 Bn | 476.28 Bn | 12.70 Bn | 49.01% |
| 4 | Merck | 365.23 Bn | 319.60 Bn | 12.21 Bn | 6.02% |
| 5 | Novartis Ag | 302.66 Bn | 266.65 Bn | 11.24 Bn | - |
| 6 | Astrazeneca | 267.39 Bn | 241.08 Bn | 12.86 Bn | 33.11% |
| 7 | Amgen | 241.61 Bn | 197.01 Bn | 7.24 Bn | 46.01% |
| 8 | Gilead Sciences | 194.67 Bn | 168.86 Bn | 6.22 Bn | -124.26% |
| 9 | Pfizer | 172.91 Bn | 119.55 Bn | 10.94 Bn | 39.16% |
| 10 | Keros Therapeutics | 224.56 Mn | -1.70 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -7,498.70% |
| Sep 30, 2025 | -105.10% |
| Jun 30, 2025 | -217.12% |
| Mar 31, 2025 | 72.14% |
| Dec 31, 2024 | -1,739.71% |
| Sep 30, 2024 | -15,036.86% |
| Jun 30, 2024 | -135,494.59% |
| Mar 31, 2024 | -58,079.52% |
| Dec 31, 2023 | -32,313.29% |
| Sep 30, 2023 | -538,375.00% |
| Mar 31, 2022 | -133.41% |
| Dec 31, 2021 | -23.81% |
| Jun 30, 2021 | -15,450.00% |
| Dec 31, 2019 | -106.76% |
| Sep 30, 2019 | -90.84% |
| Jun 30, 2019 | -104.08% |
| Mar 31, 2019 | -112.52% |
API Access
Keros Therapeutics EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=KROS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "KROS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=KROS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();